TARGINACT (oxycodone/naloxone), opioid analgesic and antagonist

No clinical benefit after failure of a dopaminergic treatment in the management of adults with very severe restless leg syndrome

• TARGINACT now has Marketing Authorisation in the second-line treatment of idiopathic restless leg syndrome (RLS) in adults, after failure of dopaminergic agonist treatment, only in patients at the severe or very severe stage.
•  Its clinical benefit is moderate in very severe RLS after failure of dopaminergic agonist treatment. It is insufficient to justify its reimbursement in other stages of this syndrome.